Interestingly, SJ3149 also inhibited several TP53-altered cell lines, such as BT-20 and KU812, suggesting that CK1α degraders may offer potential therapeutic opportunities for cancers that are insensitive to MDM2 inhibitors. This evidence concerns the gene TP53 and cancer.